We consider that this regulatory effect of Q2-3 has potential for translation into future clinical application for several reasons: Q2-3 stimulatory activity can be obtained at a very low dosage (20–100 μg kg−1 body weight), the phytochemical derivative can already be readily synthesized, and its molecular mode of action is specific, that is, it acts on the expression of an endogenous anticancer factor IL-25 against mammary tumour cells in ongoing metastasis. Here, IL25 is linked to breast cancer.